BOOST Pharma

From Research Wiki
Revision as of 07:42, 14 April 2026 by Admin 3julmthh (talk | contribs) (Added valuation: €3.1M+ (Nov 2025); est. ~€5-15M)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Template:Company

What They Do[edit]

Cell therapy for children with osteogenesis imperfecta (genetic bone disease / brittle bone disease).

Funding[edit]

Valuation: €3.1M+ (Nov 2025); est. ~€5-15M €3.1 million additional funding (November 2025).[1]

Traction[edit]

Strategic manufacturing agreement with RoslinCT for cell therapy production.[2]

See Also[edit]

  1. ↑ EU-Startups (Nov 3, 2025): "In bid to improve outcomes for children with genetic bone disease, Swedish startup BOOST Pharma raises additional €3.1 million"
  2. ↑ BioSpace (2025): "RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement"
Retrieved from "https://wiki.stamen.health/index.php?title=BOOST_Pharma&oldid=248"